Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations : Are they useful biomarkers o...
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations : Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Blackwell Publishing Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Blackwell Publishing Ltd
Subjects
More information
Scope and Contents
Contents
KRAS mutations have been identified as a strong predictor of resistance to anti‐epidermal growth factor receptor (EGFR) therapies. Besides inhibiting the EGFR pathway, anti‐EGFR monoclonal antibodies may exert antitumor effects through antibody‐dependent cell‐mediated cytotoxicity (ADCC). Through this mechanism, the antibody fragment C portion (Fcγ...
Alternative Titles
Full title
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations : Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11158139
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11158139
Other Identifiers
ISSN
1347-9032,1349-7006
E-ISSN
1349-7006
DOI
10.1111/j.1349-7006.2010.01621.x
